V. Sutton

发表

Quality of Life Assessment in Adult Patients With Attention-deficit/Hyperactivity Disorder Treated With Atomoxetine

Rodney J. Moore, L. Adler, K. Secnik, 2006, Journal of clinical psychopharmacology.

Change in extrapyramidal symptoms with olanzapine in comparison with other antipsychotic agents

K. Meehan, V. Sutton, S. David, 2000, Schizophrenia Research.

Change in positive symptoms with olanzapine compared to other antipsychotic agents

K. Meehan, V. Sutton, S. David, 1999, European Neuropsychopharmacology.

Treatment of negative symptoms with olanzapine in comparison with other novel antipsychotic agents

K. Meehan, V. Sutton, S. David, 1999, European Neuropsychopharmacology.

Effects of atomoxetine and methylphenidate on sleep in children with ADHD.

K. Schuh, J. Owens, A. Allen, 2006, Sleep.

Once-daily atomoxetine treatment for children with attention-deficit/hyperactivity disorder, including an assessment of evening and morning behavior: a double-blind, placebo-controlled trial.

K. Schuh, D. Coury, A. Allen, 2004, Pediatrics.

The Life Participation Scale for Attention-Deficit/Hyperactivity Disorder--Child Version: psychometric properties of an adaptive change instrument.

K. Schuh, D. Faries, K. Saylor, 2007, Journal of child and adolescent psychopharmacology.

ATOMOXETINE TREATMENT FOR PEDIATRIC PATIENTS WITH ADHD AND COMORBID ANXIETY

P. Trzepacz, L. Sher, L. Sher, 2006 .

Characteristics of placebo responders in pediatric clinical trials of attention-deficit/hyperactivity disorder.

T. Wilens, J. Newcorn, C. Kratochvil, 2009, Journal of the American Academy of Child and Adolescent Psychiatry.

Olanzapine in the treatment of dopamimetic-induced psychosis in patients with Parkinson’s disease

J. Friedman, A. Breier, P. Feldman, 2002, Biological Psychiatry.

Variation in Catechol-O-Methyltransferase Is Associated with Duloxetine Response in a Clinical Trial for Major Depressive Disorder

M. Trivedi, R. Perlis, B. Fijal, 2009, Biological Psychiatry.

Subjective and objective measures of sleep in children with attention-deficit/hyperactivity disorder.

J. Owens, A. Allen, R. Sangal, 2009, Sleep medicine.

Placebo-controlled study of the effects of atomoxetine on bladder control in children with nocturnal enuresis.

K. Schuh, V. Sutton, D. Kelsey, 2006, Journal of child and adolescent psychopharmacology.

A double-blind, placebo-controlled dose-response comparison of intramuscular olanzapine and haloperidol in the treatment of acute agitation in schizophrenia.

R. Palmer, A. Breier, M. Birkett, 2002, Archives of general psychiatry.

Atomoxetine treatment for pediatric patients with attention-deficit/hyperactivity disorder with comorbid anxiety disorder.

J. Newcorn, D. Geller, R. Rubin, 2007, Journal of the American Academy of Child and Adolescent Psychiatry.

Clinical responses to atomoxetine in attention-deficit/hyperactivity disorder: the Integrated Data Exploratory Analysis (IDEA) study.

J. Newcorn, M. Weiss, V. Sutton, 2009, Journal of the American Academy of Child and Adolescent Psychiatry.

Genetic association study of treatment response with olanzapine/fluoxetine combination or lamotrigine in bipolar I depression.

R. Perlis, M. Farmen, A. Breier, 2010, The Journal of clinical psychiatry.

Number Needed to Treat (NNT) and Number Needed to Harm (NNH) in Randomized, Blinded Trials Comparing Olanzapine to Other Atypical Antipsychotics for Treatment of Schizophrenia

M. Tohen, T. Treuer, H. Ascher-Svanum, 2008 .

Once-Daily Atomoxetine for Treating Pediatric Attention-Deficit/Hyperactivity Disorder: Comparison of Morning and Evening Dosing

K. Schuh, D. Coury, A. Allen, 2009, Clinical pediatrics.

A Double-Blind, Randomized, Placebo-Controlled Trial of Olanzapine in the Prevention of Psychotic Relapse

G. Tollefson, C. Beasley, V. Sutton, 2003, Journal of clinical psychopharmacology.

Number Needed to Treat or Harm Analyses of Olanzapine for Maintenance Treatment of Bipolar Disorder

M. Tohen, Elisabeth K. Degenhardt, V. Sutton, 2009, Journal of clinical psychopharmacology.

Maintenance of response following stabilization of mixed index episodes with olanzapine monotherapy in a randomized, double-blind, placebo-controlled study of bipolar 1 disorder.

J. Calabrese, M. Tohen, G. Sachs, 2009, Journal of affective disorders.

Olanzapine in the treatment of anxiety symptoms due to Alzheimer's disease: a post hoc analysis

J. Mintzer, A. Breier, V. Sutton, 2001, International journal of geriatric psychiatry.

Comparison of risperidone and olanzapine in the control of negative symptoms of chronic schizophrenia and related psychotic disorders in patients aged 50 to 65 years.

G. Tollefson, A. Breier, P. Feldman, 2003, The Journal of clinical psychiatry.

Describing scales of features in river channels using fractal geometry concepts

John M. Nestler, Virginia Kay Sutton, J. Nestler, 2000 .

Safety and tolerability of once versus twice daily atomoxetine in adults with ADHD.

L. Taylor, L. Adler, A. Allen, 2006, Annals of clinical psychiatry : official journal of the American Academy of Clinical Psychiatrists.

Is Quality of Life Among Minimally Symptomatic Patients With Schizophrenia Better Following Withdrawal or Continuation of Antipsychotic Treatment?

D. Naber, G. Sethuraman, C. Beasley, 2006, Journal of clinical psychopharmacology.

Superiority of olanzapine over risperidone in the control of negative symptoms of schizophrenia and related psychotic disorders in older patients

A. Breier, P. Feldman, V. Sutton, 2001, European Neuropsychopharmacology.

Effectiveness and Safety of the Combination of Fluoxetine and Olanzapine in Outpatients With Bipolar Depression: An Open-Label, Randomized, Flexible-Dose Study in Puerto Rico

M. Tohen, E. Vieta, V. Sutton, 2009, Journal of clinical psychopharmacology.